https://charts.traderzeitung.de/phases/US5787841007
string(1460) "{"isin":"US5787841007","name":"Maze Therapeutics Inc","stock_id_xnas":72754800,"stock_id_xnys":null,"generated_at":"2026-08-21 14:35:00","days":[{"date":"2026-08-18","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":27.03,"close_at":"2026-08-18 15:25:00","complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":29.17,"close_at":"2026-08-18 21:59:00","complete":true,"perf_pct":7.9171},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-19","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":30.85,"close_at":"2026-08-19 15:25:00","complete":true,"perf_pct":5.7593},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":29.78,"close_at":"2026-08-19 21:59:00","complete":true,"perf_pct":-3.4684},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":29.43,"close_at":"2026-08-19 22:00:00","complete":true,"perf_pct":-1.1753}]},{"date":"2026-08-20","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":28.94,"close_at":"2026-08-20 21:59:00","complete":true,"perf_pct":-1.665},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"
Maze Therapeutics Aktie News & Nachrichten

Maze Therapeutics Aktie News & Nachrichten

[WKN: A41188 | Symbol: MAZE]
Realtimekurs
   
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Maze Therapeutics: BTIG spricht Kaufempfehlung mit rund 100 % Kurspotenzial aus!

Maze Therapeutics (MAZE) konzentriert sich auf die Entwicklung von Präzisionsmedikamenten, die auf...

Maze Therapeutics (MAZE): Nach dem IPO im Fokus der Analysten - Experten sehen bis zu 175 % Kurspotenzial!

Maze Therapeutics Inc. (MAZE) hat sich auf Präzisionsmedikamente für genetische Krankheiten spezialisiert....

TOP-5-Kursziele der Analysten am 25.02.25

SFC Energy [DE0007568578]: Warburg Research bestätigt Buy-Rating mit Kursziel 27 Euro (50 % Kurspotenzial)...

  • 1
MT Newswires 11.08.2026 22:34 Uhr

-- Earnings Flash (MAZE): Maze Therapeutics verzeichnet im Q2 einen Verlust von 0,76 USD je Aktie, verglichen mit der FactSet-Schätzung von 0,72 USD Verlust

04:33 PM EDT, 08/11/2026 (MT Newswires) -- http://www.mtnewswires.com Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provid